JF
GLUE icon

Jump Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

Jump Financial’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.04M Buy
+184,522
New +$3.53M 0.04% 497
2025
Q1 		– Sell
-154,842
Closed -$1.07M – 1751
2024
Q4 		$1.07M Buy
+154,842
New +$1.16M 0.02% 731
2024
Q3 		– Sell
-16,338
Closed -$61.1K – 1822
2024
Q2 		$61.1K Sell
16,338
-560
-3% -$2.85K ﹤0.01% 1679
2024
Q1 		$119K Buy
+16,898
New +$100K ﹤0.01% 1769
2022
Q4 		– Sell
-18,200
Closed -$149K – 1741
2022
Q3 		$149K Buy
+18,200
New +$167K 0.01% 1399

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Jump Financial's GLUE Position: Q1 2026 in Review

Jump Financial opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 184,522 shares worth $3.04M. The stake represents 0.04% of the portfolio and ranks #497 among its holdings. This is a return to the name: Jump Financial previously reported a position in GLUE as recently as Q4 2024.

Jump Financial first reported a position in GLUE in Q3 2022 and has held it in 5 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Jump Financial held 184,522 shares of Monte Rosa Therapeutics worth $3.04M as of Q1 2026.
  • Monte Rosa Therapeutics was a new Jump Financial position in Q1 2026.
  • Monte Rosa Therapeutics made up 0.04% of Jump Financial's portfolio in Q1 2026, its #497 holding.
  • Jump Financial first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.